Skip to Content
Merck
All Photos(1)

Key Documents

Y0000382

Famotidine for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Famotidine, N′-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C8H15N7O2S3
CAS Number:
Molecular Weight:
337.45
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

famotidine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N\C(N)=N\c1nc(CSCCC(=N)NS(N)(=O)=O)cs1

InChI

1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

InChI key

XUFQPHANEAPEMJ-UHFFFAOYSA-N

Gene Information

human ... HRH2(3274)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Famotidine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

H2 histamine receptor antagonist; anti-ulcer agent

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R R Berardi et al.
Clinical pharmacy, 7(4), 271-284 (1988-04-01)
The pharmacodynamic, therapeutic, and toxicologic properties of famotidine are evaluated and compared with those of cimetidine and ranitidine. Famotidine, an H2-receptor antagonist with a thiazole nucleus, is approximately 7.5 times more potent than ranitidine and 20 times more potent than
I C Wesdorp
Hepato-gastroenterology, 39 Suppl 1, 24-26 (1992-02-01)
Famotidine, a potent and long-acting H2-receptor antagonist, has been evaluated in patients with gastroesophageal reflux disease (GERD). From intraesophageal pH monitoring and clinical studies, b.i.d. dosing of this selective compound is necessary for achieving adequate results. The results of large
K Yoshimoto et al.
Clinical pharmacology and therapeutics, 55(6), 693-700 (1994-06-01)
Central nervous system toxicity of H2-receptor antagonists has rarely been confirmed by the respective elevated cerebrospinal fluid drug concentrations. We observed two hemodialyzed neurosurgical patients in whom mental deterioration and convulsions developed after intravenous famotidine therapy (10 and 40 mg/day).
Michael Schiff et al.
Expert review of gastroenterology & hepatology, 6(1), 25-35 (2011-12-14)
Arthritis affects nearly 50 million people in the USA and, with the aging of the population, the prevalence is expected to rise. While NSAIDs are very effective in relieving pain associated with osteoarthritis (OA) and rheumatoid arthritis (RA), they are
C W Howden et al.
Clinical therapeutics, 18(1), 36-54 (1996-01-01)
Famotidine is a specific, long-acting histamine2-receptor antagonist. It is indicated for the treatment of duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. Since its introduction for the treatment of acid-related disorders in 1985, an estimated 18.8 million patients

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service